[ad_1]
British firefighter preparing the AstraZeneca vaccine (February 4) Peter Cziborra-REUTERS
<¿Cuál es el problema de la vacuna, que fue interrumpida por el presidente francés Emmanuel Macron por ser "casi ineficaz para las personas mayores de 65 años" y de repente se detuvo en Sudáfrica?>
[Desde Londres]A new coronavirus vaccine developed and manufactured jointly by the University of Oxford in the UK and AstraZeneca, a major UK pharmaceutical company, is exposed to strong headwinds. Despite the European Union (EU) European Medicines Agency (EMA) approving emergency use for people over 18 years of age, EU member states such as Germany and France have forgotten vaccines for people over 65 years. The United States has not even approved it.South Africa also stopped vaccination with the AstraZeneca vaccine, as it was found to reduce its effectiveness against South African mutants avoiding immunity to 22%. Professor Sarah Gilbert of the Jenner Institute at the University of Oxford, who leads the development of the vaccine, told the BBC broadcast on the 7th that “a vaccine that works against the South African mutant strain can be prepared for the fall.” and the secret plan for the third inoculation in the fall made you sick …
In the UK, vaccination surpassed 12 million people on the same day, and by February 15, we achieved the goal of completing the first vaccination for 70 high-risk groups, care center staff and healthcare workers. years or older and have an underlying disease. Approaches. On the other hand, EU member states like Germany and France were completely late. This is because the EU was unable to purchase the Aota vaccine. In addition to this, the late delivery of AstraZeneca has infuriated the EU member states.
French President Emmanuel Macron said on January 29, hours before the EMA recommended the use of the AstraZeneca vaccine for people over the age of 18, “It currently has little effect in people over 65. Initial results are 60. – I have not”. Those over 65 are encouraged. ”The Robert Koch Institute’s Standing Committee on Immunization also recommended that vaccination only be given to children under 65.
France, Germany, Austria, Sweden, Norway (non-EU member), Denmark, the Netherlands, Spain, and Poland have recommended AstraZeneca vaccines only for those under 65 years of age. Italy and Belgium are recommended only for those under 55 years of age. Switzerland (non-EU member) did not approve (BBC summary).
What are the three problems with the AstraZeneca vaccine?
From my point of view, there are three problems with the AstraZeneca vaccine.
(1) Insufficient results of phase 3 study
(2) There was a problem with mass production.
(3) Low efficacy against South African mutants with “E484K” mutations that prevent immunity
In November last year, the University of Oxford and AstraZeneca announced the interim results of a phase 3 study involving more than 23,000 people over the age of 18 (including 131 affected) in the UK and Brazil. 90% efficacy in the group (2741 subjects) receiving the second dose of the full dose one month after halving the first intake, 62 in the group receiving the full dose both times (8895 subjects). The validity of% was demonstrated. The mean was 70.4%.
[ad_2]
